Researchers from Exscientia, the Medical University of Vienna, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences demonstrated the impact of using Exscientia’s AI-supported precision medicine platform to propose which therapy would be most effective for late-stage hematological cancer patients, based on testing drug responses ex vivo in their own tissue samples.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
